{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["38(9)"],"submitter":["Syed YY"],"pubmed_abstract":["RTS,S/AS01 (Mosquirix<sup>®</sup>) is a vaccine against malaria caused by <i>Plasmodium falciparum</i>. In a phase 3 trial, RTS,S/AS01 showed vaccine efficacy against clinical malaria, severe malaria and malaria hospitalization, with an acceptable safety and tolerability profile, in children aged 6 weeks to 17 months; the vaccine efficacy was greater in children than in infants and waned over time. In another phase 3 trial, RTS,S/AS01 was noninferior to seasonal malaria chemoprevention in children. WHO recommends a 4-dose schedule of RTS,S/AS01 for the prevention of <i>P. falciparum</i> malaria in children from 5 months of age living in regions with moderate to high malaria transmission, with an optional 5-dose schedule for areas with highly seasonal malaria transmission. First results fro"],"journal":["Drugs & therapy perspectives : for rational drug selection and use"],"pagination":["373-381"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9449949"],"repository":["biostudies-literature"],"pubmed_title":["RTS,S/AS01 malaria vaccine (Mosquirix<sup>®</sup>): a profile of its use."],"pmcid":["PMC9449949"],"pubmed_authors":["Syed YY"],"additional_accession":[]},"is_claimable":false,"name":"RTS,S/AS01 malaria vaccine (Mosquirix<sup>®</sup>): a profile of its use.","description":"RTS,S/AS01 (Mosquirix<sup>®</sup>) is a vaccine against malaria caused by <i>Plasmodium falciparum</i>. In a phase 3 trial, RTS,S/AS01 showed vaccine efficacy against clinical malaria, severe malaria and malaria hospitalization, with an acceptable safety and tolerability profile, in children aged 6 weeks to 17 months; the vaccine efficacy was greater in children than in infants and waned over time. In another phase 3 trial, RTS,S/AS01 was noninferior to seasonal malaria chemoprevention in children. WHO recommends a 4-dose schedule of RTS,S/AS01 for the prevention of <i>P. falciparum</i> malaria in children from 5 months of age living in regions with moderate to high malaria transmission, with an optional 5-dose schedule for areas with highly seasonal malaria transmission. First results fro","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-28T05:40:44.321Z","creation":"2025-02-19T04:38:13.246Z"},"accession":"S-EPMC9449949","cross_references":{"pubmed":["36093265"],"doi":["10.1007/s40267-022-00937-3"]}}